FDA Accepts Pharvaris' NDA for Deucrictibant IR in HAE Treatment
Event summary
- Pharvaris' New Drug Application (NDA) for deucrictibant IR in treating hereditary angioedema (HAE) attacks has been accepted by the FDA.
- The Prescription Drug User Fee Act (PDUFA) target action date is set for April 23, 2027.
- Clinical data from over 1,300 HAE attacks showed rapid symptom relief and a well-tolerated safety profile.
- Deucrictibant IR demonstrated median time to onset of symptom relief at 1.28 hours and complete resolution in 11.95 hours.
The big picture
Pharvaris' NDA acceptance marks a significant step in the development of an oral bradykinin B2 receptor antagonist for HAE, potentially offering a new treatment option with rapid symptom relief. The FDA's review process will be critical in determining the drug's market entry and competitive positioning within the bradykinin-mediated disease space.
What we're watching
- Regulatory Approval
- Whether the FDA will approve deucrictibant IR by the PDUFA action date of April 23, 2027.
- Commercial Readiness
- The pace at which Pharvaris can build out its commercial infrastructure for a potential launch.
- Market Positioning
- How deucrictibant IR will compete against existing therapies for HAE if approved.
Related topics